The purpose of this study was to estimate the cost of generic drug development and approval. This study develops an analytical framework for examining the expected net present value (ENPV) (i.e., the difference between the present value of expected revenues over product life and cost of product development and approval) to a generic drug developer in different size drug markets.
Prescription Drugs
Reports
Displaying 51 - 60 of 103. 10 per page. Page 6.
Advanced SearchASPE Data Point
Prescription Drug Affordability among Medicare Beneficiaries
More than 5 million Medicare beneficiaries struggle to afford prescription medications. Among adults 65 and older, Black and Latino beneficiaries are most likely to experience affordability problems. Medicare beneficiaries with lower incomes and those under age 65 also had above-average rates of not taking needed medications due to cost.
Report
Prescription Drug Supply Chains: An Overview of Stakeholders and Relationships
Many stakeholders and steps are involved in the life cycle of a prescription drug as it moves from chemical synthesis and formulation through dispensing or administration to patients. The specific steps involved in prescription drug supply chains often differ depending on the type of drug, the channel of distribution, and the patient’s source of prescription drug coverage.
Report
Assessing Relationships between Drug Shortages in the United States and Other Countries
Drug shortages are a persistent public health problem in the United States and in other countries. Shortages can have important implications for the health care systems and pharmacies that purchase, store, and dispense drugs and for the patients who rely on the availability of drugs to treat and prevent disease.
Report
Comprehensive Plan for Addressing High Drug Prices: A Report in Response to the Executive Order on Competition in the American Economy
President Biden’s Executive Order 14036, “Promoting Competition in the American Economy” (the Competition Executive Order), identifies a lack of competition as a key driver for problems across economic sectors.
Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey
This study presents the findings of a national survey of physicians about their knowledge of biosimilar biological products as well as the impact of biological product naming conventions on prescriber choice.
Related Products
ASPE Issue Brief
Trends in Hospital Readmission and Emergency Department Visit among Infants Born with Neonatal Abstinence Syndrome Issue Brief
Trends in Hospital Readmission and Emergency Department Visit among Infants Born with Neonatal Abstinence Syndrome ASPE ISSUE BRIEF Mir M. Ali, Emma Nye, and Kristina West U.S. Department of Health and Human Services
ASPE Issue Brief
Use of Outpatient Pharmacological Treatment Among Infants Born with Neonatal Abstinence Syndrome: Medicaid 2008-2017 Issue Brief
Use of Outpatient Pharmacological Treatment Among Infants Born with Neonatal Abstinence Syndrome: Medicaid 2008-2017 ASPE ISSUE BRIEF Mir M. Ali, Emma Nye, and Kristina West U.S. Department of Health and Human Services
ASPE Issue Brief
How Does DATA-Waiver Provider Patient Capacity Relate to Opioid and Buprenorphine Prescribing? Issue Brief
How Does DATA-Waiver Provider Patient Capacity Relate to Opioid and Buprenorphine Prescribing? Issue Brief Robin Ghertner and Mir M. Ali U.S. Department of Health and Human Services
ASPE Issue Brief
Postpartum Opioid Prescription Fills, Opioid Use Disorder, and Utilization of Medication-Assisted Treatment among Women with Medicaid and Private Health Insurance Coverage Issue Brief
Postpartum Opioid Prescription Fills, Opioid Use Disorder, and Utilization of Medication-Assisted Treatment among Women with Medicaid and Private Health Insurance Coverage Issue Brief Mir M. Ali, Kristina West, and Emma Nye U.S. Department of Health and Human Services